AdCMVp53

AdCMVp53 is an adenoviral vector-based gene therapy encoding wild-type human p53 under control of the cytomegalovirus (CMV) promoter. It is designed for direct delivery of functional p53 into tumor cells lacking effective p53, thereby inducing cell cycle arrest or apoptosis. This agent has been investigated primarily for the treatment of cancers with p53 mutation, including ovarian cancer[2], head and neck squamous cell carcinoma, hepatocellular carcinoma, lung cancer, and others. Restoring p53 function aims to suppress tumor growth, enhance chemosensitivity, and overcome resistance to conventional therapies[1][2][3][5].

Other names

AdCMVp53AdCMVp-53AdCMVp 53Ad-CMV-p53Ad-CMV-p-53Ad-CMV-p 53adenovirus-based p53 gene therapyadenoviral vector p53